Search

Your search keyword '"Ubals, Maria"' showing total 24 results
Start Over Author "Ubals, Maria" Search Limiters Peer Reviewed
24 results on '"Ubals, Maria"'

1. Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study

Author

Alarcón Soto, Yovaninna, Alemany, Andrea, Bailón, Lucía, Benet, Susana, Mitjà, Oriol, Mothe, Beatriz, Paredes, Roger, Sabato, Sofía, Suñer, Clara, Torrano, Pamela, Ubals, Maria, Boreika, Rytis, Brander, Christian, Carabelli, Julieta, Carrillo, Jorge, Gallemí, Marçal, Izquierdo-Useros, Nuria, Molina-Molina, Elisa, Moraes-Cardoso, Igor, Muñoz-Basagoiti, Jordana, Olvera, Alex, Perez-Zsolt, Daniel, Raïch-Regué, Dàlia, Coll, Pep, Fernández, Javier, Mendoza, Adrià, Pérez, Félix, Reguant, Joan, Rivero, Angel, Arando, Maider, Descalzo, Vicente, Néstor Garcia, Jorge, Monforte, Arnau, Álvarez, Patricia, Guedj, Jeremie, Marc, Aurélien, Marks, Michael, Alarcón-Soto, Yovaninna, Grifoni, Alba, Sette, Alessandro, and Moltó, José

Published
2024
Full Text
View/download PDF

2. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial

Author

Ubals, Maria, Nadal-Baron, Patricia, Arando, Maider, Rivero, Ángel, Mendoza, Adrià, Descalzo Jorro, Vicent, Ouchi, Dan, Pérez-Mañá, Clara, Álvarez, Marlene, Alemany, Andrea, Hoyos-Mallecot, Yannick, Nunley, Ethan, Lieberman, Nicole A P, Greninger, Alexander L, Galván-Casas, Cristina, Suñer, Clara, G-Beiras, Camila, Paredes, Roger, Rodríguez-Gascón, Alicia, Canut, Andrés, García-Patos, Vicente, Farré, Magí, Marks, Michael, Giacani, Lorenzo, Vall-Mayans, Martí, and Mitjà, Oriol

Published
2024
Full Text
View/download PDF

4. Mpox in people with advanced HIV infection: a global case series

Author

Leiro, Viviana, Marchetta, Lucila, Fernandez Pardal, Patricia, Figueroa, María Inés, Cahn, Pedro, Grabmeier-Pfistershammer, Katharina, Libois, Agnes, Liesenborghs, Laurens, Grinsztejn, Beatriz, Schechter, Mauro, dos Santos de Lemos, Alberto, Furtado Costa, Alvaro, Queiroz Rocha, Simone, Valdez Madruga, José, S. Tan, Darrell H., Mishra, Sharmistha, Shah, Shreya, Jorquera, Camila, Castillo, Alberto, Carrión, Mauricio, Cevallos, Nelson, Palich, Romain, Pourcher, Valerie, Rubenstein, Emma, Migaud, Pascal, Boesecke, Christoph, Hoffmann, Christian, Protopapas, Konstantinos, Nozza, Silvia, Cattelan, Anna Maria, Mussini, Cristina, d'Arminio Monforte, Antonella, Cruz Flores, Raúl Adrian, Pérez Barragán, Edgar, Rodríguez Guzmán, Alma Leticia, Ogoina, Dimie, Chika-Igwenyi, Nneka Marian, Chizaram, Onyeaghala, Valverde López, Jenny, García Tello, Angelica, Ubals, Maria, Vall, Martí, Mendoza, Adrià, Suñer, Clara, Clotet, Bonaventura, Bechini, Jordi, Lepe, Jose A, Navarro-Amuedo, M. Dolores, Bernadino, Jose Ignacio, Català, Alba, Tarín Vicente, Eloy José, González Rodríguez, Borja, Rodriguez-Mercader, Sergi, Sánchez-Martinez, Francisca, Cañas-Ruano, Esperanza, Parra-Navarro, Laura, Filén, Finn, Tallón de Lara, Carmen, Braun, Dominique, Piezzi, Vanja, Burkhard, Michael, Kovari, Helen, Mönch, Anja, Dunning, Jake, Simoes, Pedro, Nori, Achyuta, Keegan, Sarah, Thornhill, John P, Apea, Vanessa, Noori, Teymur, Jones, Joyce L., Judson, Seth, Gilliams, Elizabeth A., Hamill, Matthew M., Keruly, Jeanne, Henao Martínez, Andrés F., Lin, Aung, So, Jessica, Davar, Kusha, Villareal, Diana, Tapia Paredes, Miguel, Mitjà, Oriol, Alemany, Andrea, Marks, Michael, Lezama Mora, Jezer I, Rodríguez-Aldama, Juan Carlos, Torres Silva, Mayara Secco, Corral Herrera, Ever Arturo, Crabtree-Ramirez, Brenda, Blanco, José Luis, Girometti, Nicolo, Mazzotta, Valentina, Hazra, Aniruddha, Silva, Macarena, Montenegro-Idrogo, Juan José, Gebo, Kelly, Ghosn, Jade, Peña Vázquez, María Fernanda, Matos Prado, Eduardo, Unigwe, Uche, Villar-García, Judit, Wald-Dickler, Noah, Zucker, Jason, Paredes, Roger, Calmy, Alexandra, Waters, Laura, Galvan-Casas, Cristina, Walmsley, Sharon, and Orkin, Chloe M

Published
2023
Full Text
View/download PDF

5. Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial

Author

Aguilar-Uroz, Adrià, Rosell-García-Ufano, Adrià, Escudero Planas, Adrián, Baelo, Aida, Villahoz Martín, Ainhoa, Moreno López, Alberto, Roldan Ruiz, Alberto, Santana Briongos, Alberto, Tejera Bodas, Alberto, Alonso-Vallés, Alejandro, Fletes-Pérez, Alejandro, Hueso-Mor, Alejandro, Boluda, Alex, Santamaria, Alex, Diestro, Alicia Santos, Revuelta-Álvarez, Almudena, Moreno Moreno, Álvaro, Ortega de Felipe, Ana, Chen-Ye, Ana, Blázquez Valerón, Ana, Rodríguez Pérez, Ana Belén, Tristán Morgalo, Ana Laura, Fernández-Allende, Ana Luisa, Bagán-Trejo, Andrea, Fernández Juan, Andrés, Zalve-Cano, Ángel, Mateo-Martínez, Anna, Galván, Antonio Valero, Egidos-Plaja, Antonio, Jorge, Ariadna, Fraile Torres, Arturo, Pareja Leal, Azahara Maria, Viader Castro, Bárbara, Fernandez Beato, Barbara, Naveira Menchen, Barbara, Martin Poyatos, Beatriz, García-Martínez, Beatriz, Rodrigo Testillano, Belén, Blanco Tejedor, Belen, López Pérez, Blanca, Mencía Hernanz, Blanca, González-Beiras, Camila, Batres, Carlos, Nuñez Garcia, Carmen, Merino-Rodríguez, Carmen, Rodríguez-Gilabert, Carolina, Bonilla Penedo, Celia, Casado Gomez, Christian, Gonzalez Perez, Claudia, Galindo-Tomás, Claudia, Peral Bolaños, Cristina, Blanco-Montes, Cristina, Lupu-Yakovleva, Cristina, Lopez Ruiz, Cristina, Perez Mayoral, Cristina, Fornes, Cristina, Garcia Corrochano, Cristobal, Gallardo Álvarez, Daniel, Navarro Sanz, Daniel, Sanz Barrio, David, Ramet Meseguer, Debora, Vera-Jurado, Edna Margarita, Perez Costa, Eduardo, Bustillos-Sebastian, Eilen Junet, Palomar Casado, Elena, Guerrero, Elena Dorrego, Medina Mateos, Elena, Aragón Gaspar, Elisa Rebeca, Herrero-Vila, Elisabeth, Paez Herrera, Enriqueta, Rojas Powel, Esmeralda, Robres Medialdea, Esther, Vall-Ribalta, Esther, Lopez Perez, Eva, Mihaela Fer, Felicia, Vazquez Ángeles, Fernanda, Tirado Bejarano, Fernando, Prats-Domenech, Ferran, Borràs Martí, Ferran, Ardila-Mejia, Gabriela, Costes, Gèlia, Gómez Arquero, Gema, Flores Mateo, Gemma, Pintos-Morell, Guillem, Mira-Centelles, Helena, Astola Requena, Ignacio, Ortega Martin, Ignacio, Leivas-Gutierrez, Iker, Escribano Valenciano, Irene, Muñoz Gomez, Irene, Ortega, Irina, Montserrat-Lloan, Isabel, Gamboa, Itziar, Rodríguez de Torres de Paul, Jacobo, Cahís, Jordi, Muñoz-Martinez, Jordi, Bermejo, Jorge Iglesias, Cejas López, Joselvis Virginia, Canudas, Josep, García Lucas, Juan Antonio, Martínez-Pino, Juan Carlos, Torres Martínez, Juana, Pujol-Corney, Judit, González Jiménez, Judith, Gurí, Júlia, Labella Martín, Julio, Garcia-Cano, Laia, Perez Plata, Lara Sonsoles, Muñoz Álvaro, Laura, Rodríguez Andrés, Laura, Vega Ruiz, Laura, Cuevas Valiente, Laura, Díaz Rodríguez, Laura, Puigros, Laura, Cristina Piciorang, Lavinia, Escudero, Leticia, Figueroa Caballero, Liliana, Ferrerfàbrega-Costals, Lluna, Costafreda-Hernández, Lucía, De-Paúl, Lucía, González Fernández-Medina, Luis, Moliner Prada, M<ce:sup loc='post">a</ce:sup> Carmen, Berriochoa Martínez de Pisón, M<ce:sup loc='post">a</ce:sup> Cristina, Blanco Blasco, Maria, Gil Jorge, Maria, Cortijo Caballero, María, Ubals, Maria, Gordillo, Maria, Guilloto López, Maria Alicia, Moreno Calvo, Maria Concepción, Gil García, María del Rosario, Dueñas Román, María Inmaculada, Gonzalez Sanchez, Maria Josefa, Nicolás Campoy, María Luisa, González Velayos, Maria Luz, Zori, Mario Mejías, Maqueda, Mario Oliva, Caño de la Cruz, Mario, Palau-Morral, Mariona, Martín-Muñoz, Marta, Cereceda Meca, Marta, Díaz Urbina, Marta, VerónicaPlazas, Martha, Vall-Mayans, Martí, Blasco, Martí, Jane Chu-Sifuentes, Mary, García de Villasladad Peñaranda, Miguel, Hernanz Sotoca, Miguel, Iglesias Gonzalez, Miguel, Labrador-Galván, Miguel Ángel, Rodrigo de Vivar Azcarate, Miguel, Gil-Fibla, Miquel, Formentí-Pallarés, Miquel, Esteve-Tugues, Mireia, Juanes Perez, Miriam, López Rubio, Miriam, Recuero Renales, Mirian, Hijós-Rullo, Mònica, Lleonart-Abadia, Montserrat, Finelli, Nadia, Rojas-Bertier, Naiara, Reyes-Calderón, Nataly, Casado Larrañaga, Nerea, Zurita Castrosin, Nerea Nuria, Álvarez-Nieto, Noélia, Leiva-Mora, Nuria, Tomillo-Martín, Olga, Belghazi, Omar, Buscà, Oriol, Mendoza Cediel, Pablo, Macedo, Pablo, Rodríguez Barroso, Patricia, Ruiz Álvarez, Patricia, López, Patricia Morales, Vara de Rey, Patricia Jimenez, Ginés, Paz Lozano, Bris Rodriguez, Pilar, Martínez-Alamillo, Pilar, Salmerón Martínez, Rafa, Botello Ariza, Raquel, Vaquero Mena, Raquel, González-Alonso, Raquel, Kaczmarczyk, Raul, Barnadas Vintró, Rita, Hontecillas Martínez, Rodrigo, Ribot-Rodríguez, Rosa, Escobar-Sánchez, Rosa, Montes Trinidad, Rosario Paloma, Martínez Quintana, Rubén, Arnay Arrogante, Ruben, Berjon Sanchez, Ruben, Picazo Navarro, Ruben, Bastos, Rubén, Martín Molinero, Samuel, Israel-Benchaya, Samuel Dan, Muñoz-Burguillo, Sandra, Rodríguez-Salvador, Sandra, Avila, Sara, Corral Gayubas, Sara, Nuñez Sánchez, Sergio, Torres Weber, Sofía, Encabo Lopez, Susana, Torices Rasines, Teresa, Sallas, Valentí, Curto-Vicente, Verónica, Gómez Hijosa, Verónica, Daimiel-Pedrote, Verónica, Gozalo, Verónica, Barrios López, Vicente, Castillo Montoya, Virginia Ivette, Espinoza Pérez, Yuri, CristinaBerriochoa Martínez de Pisón, María, Muñoz Castillo, David, Donato, Carlos, García García, Isabel, Alemany, Andrea, Millat-Martinez, Pere, Corbacho-Monné, Marc, Suñer, Clara, Galvan-Casas, Cristina, Carrera, Caty, Ouchi, Dan, Prat, Núria, Ara, Jordi, Nadal, Nuria, Riel, Ricard, Funollet, Blanca, Ojeda-Ciurana, Carmen, Balague, Lluis Esteve, Salvador-González, Betlem, Arcarons, Anna Forcada, Vidal-Alaball, Josep, Del Cura-González, María Isabel, Barrientos, Ricardo Rodríguez, Ramos-Blanes, Rafel, Bou, Alberto Alum, Mondou, Elsa, Torres, Mireia, Campins, Neus, Sanz, Ana, Tang, Yonggiang, Rodriguez-Arias, Miquel Àngel, Bassat, Quique, Clotet, Bonaventura, and Mitjà, Oriol

Published
2023
Full Text
View/download PDF

6. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study

Author

Tarín-Vicente, Eloy José, Alemany, Andrea, Agud-Dios, Manuel, Ubals, Maria, Suñer, Clara, Antón, Andrés, Arando, Maider, Arroyo-Andrés, Jorge, Calderón-Lozano, Lorena, Casañ, Cristina, Cabrera, José Miguel, Coll, Pep, Descalzo, Vicente, Folgueira, María Dolores, García-Pérez, Jorge N, Gil-Cruz, Elena, González-Rodríguez, Borja, Gutiérrez-Collar, Christian, Hernández-Rodríguez, Águeda, López-Roa, Paula, de los Ángeles Meléndez, María, Montero-Menárguez, Julia, Muñoz-Gallego, Irene, Palencia-Pérez, Sara Isabel, Paredes, Roger, Pérez-Rivilla, Alfredo, Piñana, María, Prat, Nuria, Ramirez, Aída, Rivero, Ángel, Rubio-Muñiz, Carmen Alejandra, Vall, Martí, Acosta-Velásquez, Kevin Stephen, Wang, An, Galván-Casas, Cristina, Marks, Michael, Ortiz-Romero, Pablo L, and Mitjà, Oriol

Published
2022
Full Text
View/download PDF

7. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial

Author

Ferrer, Susana, Gallardo, Mireia, Ubals, Maria, González-Beiras, Camila, Vall-Mayans, Martí, Suñer, Clara, Laporte-Villar, Clàudia, Nieto, Aroa, Comas-Leon, Xavier, Jiménez, Zahida, Ramírez-Viaplana, Ferran, Delgado-Capel, Maria, Díez Sánchez, Beatriz, Pons Barber, Maria, Gonzalez Ruiz, Cristian, Navarrete Gonzalez, Laura, González García, David, Vivero Larraza, Ainhoa, Carceles Peiró, Victor, Roquer López, Clàudia, Robert, Neus, Palet, Carles, Gudiol, Carlota, Casares Gonzalez, Pablo, Arcos Vila, Gemma, Flores Aguilera, Begoña, Rodríguez-Sevilla, Graciela, Dastis Arias, Macarena, Roca Font, Judit, Carrasco Matos, Katherine M., Saüch Valmaña, Glòria, Vidal Obradors, Carla, Tarres García, Silvia, Curriu Sabatès, Margarida, Nieto Rodríguez, Raquel, Línio, Rosa, Fornos, Míriam, Casamitjana, Natàlia, Alonso, Eva, Martínez, Núria, Maglio, Laura Analía, Comellas Fernandez, Laura, Garcia, Nadia, Hernández, Luis, González, Maria Isabel, Bravo, Anna, García, Yolanda, Sauleda Oliveras, Silvia, Vertiz, Tatiana, Benavent, Sergio, Bianco, Andrea Sofia, Verdaguer, Joaquim, Briones Zambrano, Ney Nicanor, Viozquez Meya, Maria, Hernández, Águeda, Casaña Lopez, Cristina, Bordoy, Antoni E., González Soler, Victoria, Giménez, Montserrat, París, Alexa, Marfil, Silvia, Trinité, Benjamin, Grau, Eulàlia, Alemany, Andrea, Millat-Martinez, Pere, Corbacho-Monné, Marc, Malchair, Pierre, Ouchi, Dan, Ruiz-Comellas, Anna, Ramírez-Morros, Anna, Rodríguez Codina, Joana, Amado Simon, Rosa, Videla, Sebastian, Costes, Gèlia, Capdevila-Jáuregui, Mar, Torrano-Soler, Pamela, San José, Alba, Bonet Papell, Glòria, Puig, Jordi, Otero, Aurema, Ruibal Suarez, Jose Carlos, Zarauza Pellejero, Alvaro, Llopis Roca, Ferran, Rodriguez Cortez, Orlando, Garcia Garcia, Vanesa, Vidal-Alaball, Josep, Millan, Anna, Contreras, Enric, Grifols, Joan-Ramon, Ancochea, Àgueda, Galvan-Femenia, Ivan, Piccolo Ferreira, Francini, Bonet, Mireia, Cantoni, Jordi, Prat, Núria, Ara, Jordi, Forcada Arcarons, Anna, Farré, Magí, Pradenas, Edwards, Blanco, Julià, Àngel Rodriguez-Arias, Miquel, Fernández Rivas, Gema, Marks, Michael, Bassat, Quique, Blanco, Ignacio, Baro, Bàrbara, Clotet, Bonaventura, and Mitjà, Oriol

Published
2022
Full Text
View/download PDF

8. Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison

Author

Baro, Bàrbara, Rodo, Pau, Ouchi, Dan, Bordoy, Antoni E., Saya Amaro, Emilio N., Salsench, Sergi V., Molinos, Sònia, Alemany, Andrea, Ubals, Maria, Corbacho-Monné, Marc, Millat-Martinez, Pere, Marks, Michael, Clotet, Bonaventura, Prat, Nuria, Estrada, Oriol, Vilar, Marc, Ara, Jordi, Vall-Mayans, Martí, G-Beiras, Camila, Bassat, Quique, Blanco, Ignacio, and Mitjà, Oriol

Published
2021
Full Text
View/download PDF

12. Referral of Patients to Dermatology and Teledermatology Consultations in Spain. DIADERM Study

Author

Buendía, Agustín, Fernández-Crehuet, Pablo, Husein-ElAhmed, Husein, Vega, Jesús, Viera, Agustín, Manuel Carrascosa, José, Ferrán, Marta, Gómez, Enrique, Ascanio, Lucia, García Doval, Ignacio, Arias, Salvador, Gilaberte, Yolanda, Sánchez, Juan A., Serrano, Amalia, Castillo, Rosa, Fernandez, Ramón, Armario, José, Lluc Cantalejo, Carolina, Albarrán, Cristina, Cruz Martín, María, Martín, Juan Antonio, Barabash, Román, Pérez, Lara, Salamanca, Manuel, Hernández, Carlos, Millán, José Francisco, Ruiz, Inmaculada, Armesto, Susana, González, Marta, Beteta, Valia, Cuadrado de Valles, Concepción, Cristóbal, Pilar, Roth, María Magdalena, Garcias, Juan, Fernandez de Misa, Ricardo, García, Estela, Rivero, María del Pino, Suárez, José, Farthmann, Birgit, Álvarez, Alba, García, Irene, Morales, Caridad Elena, Zemba, María Cristina, Repiso, Trinidad, Sastre, Carmen, Ubals, María, Fernández, Alejandro, González, Urbà, Grimalt, Ramón, Gómez, Sara, López, Ingrid, Gemigniani, Franco Antonio, Izquierdo, María José, Alfageme, Fernando, Barrientos, Nuria, Pericet, Laura María, Vidal, Santiago, Camarero, Celia, Lázaro, Pablo, García, Cristina, de Pablo, María Pilar, Herranz, Pedro, del Olmo, Natalia, Castellanos, María, Jiménez, Natalia, Aboín, Sonsoles, Aldanondo, Isabel, Juanes, Adriana, Arranz, Dulce María, González, Olga, Casas, Luis, Vázquez, Juan José, Peña, Carmen, Cubero, José Luis, Feal, Carlos, Mayo, María Eugenia, Iglesias, Nicolás, Rojo, Rafael, Aniz, Elfidia, Kindem, Sabrina, Barrado, Nerea, Tirado, Marisa, Quecedo, Ester, Hernández, Isabel, Sahuquillo, Antonio, Bella, Rebeca, García, Ramón, Calle, Anaid, Messeguer, Francesc, Alfaro, Alberto, Casanova, Luisa, Aspe, Libe, Moreno, María Pilar, Trébol, Izaskun, Serrano, Gonzalo, Alcalde, Víctor Manuel, García, Patricia, Coscojuela, Carmen, González-López, G., Descalzo-Gallego, M.Á., Arias-Santiago, S., Molina-Leyva, A., Gilaberte, Y., Fernández-Crehuet, P., Husein-El Ahmed, H., Viera-Ramírez, A., Fernández-Peñas, P., Taberner, R., García-Doval, I., and Buendía-Eisman, A.

Published
2019
Full Text
View/download PDF

13. Derivación de pacientes en consulta de dermatología y de teledermatología en España. Estudio DIADERM

Author

Buendía, Agustín, Fernández-Crehuet, Pablo, Husein-ElAhmed, Husein, Vega, Jesús, Viera, Agustín, Manuel Carrascosa, José, Ferrán, Marta, Gómez, Enrique, Ascanio, Lucia, García Doval, Ignacio, Arias, Salvador, Gilaberte, Yolanda, Sánchez, Juan A., Serrano, Amalia, Castillo, Rosa, Fernandez, Ramón, Armario, José, Lluc Cantalejo, Carolina, Albarrán, Cristina, Cruz Martín, María, Martín, Juan Antonio, Barabash, Román, Pérez, Lara, Salamanca, Manuel, Hernández, Carlos, Millán, José Francisco, Ruiz, Inmaculada, Armesto, Susana, González, Marta, Beteta, Valia, Cuadrado de Valles, Concepción, Cristóbal, Pilar, Roth, María Magdalena, Garcias, Juan, Fernandez de Misa, Ricardo, García, Estela, Rivero, María del Pino, Suárez, José, Farthmann, Birgit, Álvarez, Alba, García, Irene, Morales, Caridad Elena, Zemba, María Cristina, Repiso, Trinidad, Sastre, Carmen, Ubals, María, Fernández, Alejandro, González, Urbà, Grimalt, Ramón, Gómez, Sara, López, Ingrid, Gemigniani, Franco Antonio, Izquierdo, María José, Alfageme, Fernando, Barrientos, Nuria, Pericet, Laura María, Vidal, Santiago, Camarero, Celia, Lázaro, Pablo, García, Cristina, de Pablo, María Pilar, Herranz, Pedro, del Olmo, Natalia, Castellanos, María, Jiménez, Natalia, Aboín, Sonsoles, Aldanondo, Isabel, Juanes, Adriana, Arranz, Dulce María, González, Olga, Casas, Luis, Vázquez, Juan José, Peña, Carmen, Cubero, José Luis, Feal, Carlos, Mayo, María Eugenia, Iglesias, Nicolás, Rojo, Rafael, Aniz, Elfidia, Kindem, Sabrina, Barrado, Nerea, Tirado, Marisa, Quecedo, Ester, Hernández, Isabel, Sahuquillo, Antonio, Bella, Rebeca, García, Ramón, Calle, Anaid, Messeguer, Francesc, Alfaro, Alberto, Casanova, Luisa, Aspe, Libe, Moreno, María Pilar, Trébol, Izaskun, Serrano, Gonzalo, Alcalde, Víctor Manuel, García, Patricia, Coscojuela, Carmen, González-López, G., Descalzo-Gallego, M.Á., Arias-Santiago, S., Molina-Leyva, A., Gilaberte, Y., Fernández-Crehuet, P., Husein-El Ahmed, H., Viera-Ramírez, A., Fernández-Peñas, P., Taberner, R., García-Doval, I., and Buendía-Eisman, A.

Published
2019
Full Text
View/download PDF

14. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.

Author

Nguyen, Bach Tran, Marc, Aurélien, Suñer, Clara, Marks, Michael, Ubals, Maria, Hernández-Rodríguez, Águeda, Melendez, María Ángeles, Hruby, Dennis E., Russo, Andrew T., Mentré, France, Mitjà, Oriol, Grosenbach, Douglas W., and Guedj, Jérémie

Subjects
MONKEYPOX, BASIC reproduction number, REPRODUCTION, PEAK load, DRUG efficacy, VIRAL load
Abstract

Despite use of tecovirimat since the beginning of the 2022 outbreak, few data have been published on its antiviral effect in humans. We here predict tecovirimat efficacy using a unique set of data in nonhuman primates (NHPs) and humans. We analyzed tecovirimat antiviral activity on viral kinetics in NHP to characterize its concentration–effect relationship in vivo. Next, we used a pharmacological model developed in healthy volunteers to project its antiviral efficacy in humans. Finally, a viral dynamic model was applied to characterize mpox kinetics in skin lesions from 54 untreated patients, and we used this modeling framework to predict the impact of tecovirimat on viral clearance in skin lesions. At human-recommended doses, tecovirimat could inhibit viral replication from infected cells by more than 90% after 3 to 5 days of drug administration and achieved over 97% efficacy at drug steady state. With an estimated mpox within-host basic reproduction number, R0, equal to 5.6, tecovirimat could therefore shorten the time to viral clearance if given before viral peak. We predicted that initiating treatment at symptom onset, which on average occurred 2 days before viral peak, could reduce the time to viral clearance by about 6 days. Immediate postexposure prophylaxis could not only reduce time to clearance but also lower peak viral load by more than 1.0 log10 copies/mL and shorten the duration of positive viral culture by about 7 to 10 days. These findings support the early administration of tecovirimat against mpox infection, ideally starting from the infection day as a postexposure prophylaxis. Despite its use since the beginning of the 2022 mpox outbreak, few data have been published on the antiviral effect of tecovirimat in humans. This study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach that combines pre-clinical and clinical data. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain.

Author

Suñer, Clara, Ubals, Maria, Tarín-Vicente, Eloy José, Mendoza, Adrià, Alemany, Andrea, Hernández-Rodríguez, Águeda, Casañ, Cristina, Descalzo, Vicente, Ouchi, Dan, Marc, Aurélien, Rivero, Àngel, Coll, Pep, Oller, Xènia, Miguel Cabrera, José, Vall-Mayans, Martí, Dolores Folgueira, María, Ángeles Melendez, María, Agud-Dios, Manuel, Gil-Cruz, Elena, and Paris de Leon, Alexia

Subjects
*MONKEYPOX, *VIRAL DNA, *COHORT analysis, *VIRAL load, *LONGITUDINAL method
Abstract

Monkeypox DNA has been detected in skin lesions, saliva, oropharynx, urine, semen, and stool of patients infected during the 2022 clade IIb outbreak; however, the viral dynamics within these compartments remain unknown. We aimed to characterise the viral load kinetics over time in various parts of the body. This was an observational, prospective, multicentre study of outpatients diagnosed with monkeypox in two hospitals and two sexual health clinics in Spain between June 28, 2022, and Sept 22, 2022. Men and women aged over 18 years were eligible if they reported having symptom onset within the previous 10 days of presentation, and were ineligible if disease was severe enough to be admitted to hospital. Samples were collected from five body locations (skin lesions, oropharynx, rectum, semen or vagina, and a dried blood spot) at six time points up to 57 days after the screening visit. Samples were analysed by quantitative PCR and a subset by cell culture. The primary endpoint was time from symptom onset to viral DNA clearance. Overall, 1663 samples were collected from 77 study participants. 75 (97%) participants were men, the median age was 35·0 years (IQR 29·0–46·0), and 39 (51%) participants were living with HIV. The median time from symptom onset to viral clearance was 25 days (95% CI 23–28) in the skin lesions, 16 days (13–19) in the oropharynx, 16 days (13–23) in the rectum, 13 days in semen (9–18), and 1 day in blood (0–5). The time from symptom onset to viral clearance for 90% of cases was 41 days (95% CI 34–47) in skin lesions and 39 days (27–56) in semen. The median viral load in skin lesions was 7·3 log 10 copies per mL (IQR 6·5–8·2) at baseline, compared with 4·6 log 10 copies per mL (2·9–5·8) in oropharyngeal samples, 5·0 log 10 copies per mL (2·9–7·5) in rectal samples, 3·5 log 10 copies per mL (2·9–4·7) in semen samples, and 4·0 log 10 copies per mL (4·0–4·0) in blood specimens. Replication-competent viruses were isolated in samples with high DNA levels (>6·5 log 10 copies per mL). In immunocompetent patients with mild monkeypox disease, PCR data alone would suggest a contact isolation period of 3 to 6 weeks but, based on detection of replication-competent virus, this time could be reduced. Based on findings from this cohort of patients, semen testing and prolonged use of condoms after recovery from monkeypox might not be necessary. University Hospital Germans Trias i Pujol and the YoMeCorono. For the Spanish translation of the abstract see Supplementary Materials section. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Evaluating the Accuracy of Self-Collected Swabs for the Diagnosis of Mpox.

Author

Ubals, Maria, Tarín-Vicente, Eloy José, Oller, Xènia, Mendoza, Adrià, Alemany, Andrea, Hernández-Rodríguez, Águeda, Casañ, Cristina, Rivero, Ángel, Coll, Pep, Cabrera, José Miguel, Vall, Martí, Agud-Dios, Manuel, Gil-Cruz, Elena, Leon, Alexia Paris de, Marinero, Aída Ramírez, Folgueira, María Dolores, Meléndez, María Ángeles, Buhiichyk, Vira, Galván-Casas, Cristina, and Paredes, Roger

Subjects
*SKIN, *MONKEYPOX, *PATIENTS, *RECTUM, *COLLECTION & preservation of biological specimens, *PHYSICIANS, *POLYMERASE chain reaction, *OROPHARYNX, *LONGITUDINAL method
Abstract

We evaluated the accuracy of patient-collected skin lesions, oropharyngeal, and rectal swabs among 50 individuals enrolled in a study of mpox viral dynamics. We found that the performance of self-collected samples was similar to that of physician-collected samples, suggesting that self-sampling is a reliable strategy for diagnosing mpox. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals.

Author

Pradenas, Edwards, Ubals, Maria, Urrea, Víctor, Suñer, Clara, Trinité, Benjamin, Riveira-Muñoz, Eva, Marfil, Silvia, Ávila-Nieto, Carlos, Rodríguez de la Concepción, María Luisa, Tarrés-Freixas, Ferran, Laporte, Josep, Ballana, Ester, Carrillo, Jorge, Clotet, Bonaventura, Mitjà, Oriol, and Blanco, Julià

Subjects
HUMORAL immunity, SARS-CoV-2, VIRAL load, COVID-19, ANTIBODY titer
Abstract

Background: Evidence on the determinants of the magnitude of humoral responses and neutralizing titers in individuals with mild COVID-19 is scarce. Methods: In this cohort study of mild COVID-19 patients, we assessed viral load (VL) by RT-qPCR at two/three time points during acute infection, and anti-SARS-CoV-2 antibodies by ELISA and plasma neutralizing responses using a pseudovirus assay at day 60. Results: Seventy-one individuals (65% female, median 42 years old) were recruited and grouped into high viral load (VL) >7.5 Log10 copies/mL (n=20), low, VL ≤7.5 Log10 copies/mL (n=22), or as Non-early seroconverters with a positive PCR (n=20), and healthy individuals with a negative PCR (n=9). Individuals with high or low VL showed similar titers of total neutralizing antibodies at day 60, irrespective of maximal VL or viral dynamics. Non-early seroconverters had lower antibody titers on day 60, albeit similar neutralizing activity as the groups with high or low VL. Longer symptom duration and older age were independently associated with increased humoral responses. Conclusions: In mild SARS-CoV-2-infected individuals, the duration of symptoms and age (but not VL) contribute to higher humoral responses. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

18. Yaws recurrence in children at continued risk of infection.

Author

González-Beiras, Camila, Marks, Michael, Quintó, Llorenç, Gavilán, Sergi, Kolmau, Reman, Ubals, Maria, Vall-Mayans, Marti, and Mitjà, Oriol

Subjects
BURULI ulcer, SYPHILIS, HEALTH facilities, ELECTRONIC health records, NEGLECTED diseases, SERODIAGNOSIS, WATCHFUL waiting
Abstract

Background: In yaws-endemic areas, children with Treponema pallidum subsp. pertenue infection may suffer recurrent episodes due to either reinfection or relapse. However, the possibility of infection with other cutaneous ulcer causative agents and difficulties in interpreting standard laboratory results challenges the estimation of yaws recurrence rates. Methods: We estimated the rates of yaws recurrences in the Lihir Island (Papua New Guinea) using two approaches: passive surveillance based on a retrospective screening of electronic medical records of cutaneous ulcers diagnosed using serological testing between 2005 and 2016, and active surveillance conducted during a cross-sectional prevalence study which included PCR analyses of ulcers of all suspected cases of yaws. The risk of recurrent infection was assessed based on data from the passive surveillance analysis and using two Cox regression models (crude and multivariate), stratified by year of index episode. Data gathered from the active surveillance was used to characterize the recurrences and no hypothesis testing was performed. Results: The electronic medical records included 6,125 patients (7,889 ulcer episodes) with documented serological results of cutaneous ulcers of which1,486 were diagnosed with yaws. Overall, 1,246/6,125 patients (20.3%) presented more than once with a cutaneous ulcer, and 103/1,486 (6.7%) patients had multiple episodes of yaws. The risk of yaws recurrence significantly increased with age and was higher in patients with ≥3 recurrent episodes. In the active surveillance, we identified 50 individuals with recurrent cutaneous ulcer that had PCR results available for both the index and recurrent episode. Of 12 individuals with T. pallidum in the index ulcer, 8 (66%) had T. pallidum in subsequent assessments, relapse related to macrolide-resistance was identified in two of these cases. Conclusions: Our results confirm the need for active follow-up of yaws patients after treatment, particularly children and individuals with a history of recurrence. Author summary: Yaws is a neglected tropical disease produced by Treponema pallidum pertenue that causes skin ulcers in children living in remote rural areas of the South Pacific and West Africa. Children aged 5–15 and individuals with a history of recurrence are at higher risk of reinfection. Although yaws can be treated with single-dose azithromycin, some children present with recurrent cutaneous ulcers; however, the prevalence and risk factors for yaws recurrence are poorly known. Our analysis of skin ulcers in Papua New Guinea revealed that up to 20% of patients who presented to a health care facility in the Lihir island of Papua New Guinea with a cutaneous ulcer experienced a recurrent episode within the 6–36 months following treatment. Nearly all individuals with recurrent yaws were children aged 15 years or younger. Besides age, the number of previous ulcers was associated with a higher risk of recurrence. The molecular analysis revealed that among cases with T. pallidum at baseline that had a recurrence, this was often related to reinfection with the same microorganism. Our results confirm the need for active follow-up of young children diagnosed with cutaneous ulcers, with particular attention to those with younger age and previous history of recurrences. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial.

Author

Mitjà, Oriol, Corbacho-Monné, Marc, Ubals, Maria, Tebé, Cristian, Peñafiel, Judith, Tobias, Aurelio, Ballana, Ester, Alemany, Andrea, Riera-Martí, Núria, Pérez, Carla A, Suñer, Clara, Laporte, Pep, Admella, Pol, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ara, Jordi, and Argimon, Josep M

Subjects
RESEARCH, COVID-19, VIRAL load, TIME, MEDICAL cooperation, TREATMENT effectiveness, RANDOMIZED controlled trials, DESCRIPTIVE statistics, HOSPITAL care, HYDROXYCHLOROQUINE, STATISTICAL sampling, EARLY medical intervention, EVALUATION, ADULTS
Abstract

Background No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19. Methods Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed with <5-day of symptom onset were assigned to receive HCQ (800 mg on day 1 followed by 400 mg once daily for 6 days) or usual care. Outcomes were reduction of viral load in nasopharyngeal swabs up to 7 days after treatment start, disease progression up to 28 days, and time to complete resolution of symptoms. Adverse events were assessed up to 28 days. Results A total of 293 patients were eligible for intention-to-treat analysis: 157 in the control arm and 136 in the intervention arm. The mean age was 41.6 years (SD, 12.6), mean viral load at baseline was 7.90 log10 copies/mL (SD, 1.82), and median time from symptom onset to randomization was 3 days. No differences were found in the mean reduction of viral load at day 3 (−1.41 vs −1.41 log10 copies/mL in the control and intervention arm, respectively) or at day 7 (−3.37 vs −3.44). Treatment did not reduce risk of hospitalization (7.1% control vs 5.9% intervention) nor shorten the time to complete resolution of symptoms (12 days, control vs 10 days, intervention). No relevant adverse events were reported. Conclusions In patients with mild COVID-19, no benefit was observed with HCQ beyond the usual care. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Changes in the microbiological diagnosis and epidemiology of cutaneous leishmaniasis in real-time PCR era: A six-year experience in a referral center in Barcelona.

Author

Silgado, Aroa, Armas, Mayuli, Sánchez-Montalvá, Adrián, Goterris, Lidia, Ubals, Maria, Temprana-Salvador, Jordi, Aparicio, Gloria, Chicharro, Carmen, Serre-Delcor, Núria, Ferrer, Berta, Molina, Israel, García-Patos, Vicenç, Pumarola, Tomas, and Sulleiro, Elena

Subjects
CUTANEOUS leishmaniasis, DIAGNOSIS, SYMPTOMS, NEGLECTED diseases, LEISHMANIASIS, BURULI ulcer
Abstract

Background: Leishmaniasis is a neglected disease caused by different species of the protozoa Leishmania spp. Cutaneous lesions are the most common clinical manifestation. This disease is prevalent in tropical and subtropical areas, including the Mediterranean basin. In Spain, Leishmania (L.) infantum is the only endemic species, but imported cases are often diagnosed. Different classical parasitological methods can be performed for cutaneous leishmaniasis (CL) diagnosis; but currently molecular techniques serve as a relevant tool for the detection and characterization of Leishmania parasites. We aimed to evaluate clinical and epidemiological characteristics of CL diagnosed patients by real-time PCR in a tertiary hospital over a six-year period. Methodology/Principal findings: Clinical, epidemiological and microbiological data were retrospectively collected and analyzed. In our study, CL was confirmed in 59 (31.4%) out of 188 patients by real-time PCR, showing an increase over recent years: 11 cases of CL between 2014 and 2016 and 48 between 2017 and 2019. Real-time PCR was performed on skin swabs and/or biopsies samples, with a positivity of 38.5% and 26.5%, respectively. Results were 100% concordant when biopsy and skin swab were performed simultaneously. L. (L.) infantum was the most frequent species detected (50%), followed by L. (L.) major (45%) and Viannia subgenus (5%), which were detected only in imported cases. L. (L.) major was almost entirely detected in travelers/migrants from Morocco. Multiple and atypical skin lesions were more common in imported cases than in autochthonous cases (44.4% vs. 21.8%). Conclusions/Significance: An increase in both autochthonous and imported CL cases has been observed in past years in our hospital. Molecular techniques assist in improving CL diagnosis and characterization of the Leishmania species, mainly in imported cases. Author summary: Leishmaniasis is a neglected disease caused by different species of the genus Leishmania. This disease is prevalent in tropical and subtropical areas, including the Mediterranean basin. In Spain, the only endemic species is L. (L) infantum, although there are cases of imported leishmaniasis due to travel and migration of people from other endemic areas. Cutaneous lesions are the most common clinical form, but L. (L) infantum can also cause mucosal or visceral involvement. Although microscopic diagnosis and skin biopsy specimens are still used in routine diagnosis for cutaneous leishmaniasis, they are time-consuming and invasive, respectively. Currently, molecular techniques, such as real-time PCR, are very sensitive tools for the detection and identification of Leishmania parasites. In addition, the skin swab sample seems to be a non-invasive alternative for the diagnosis of cutaneous leishmaniasis. In the present work, we describe the clinical characteristics of 59 patients diagnosed by real-time PCR of cutaneous leishmaniasis, as well as the molecular epidemiology of the causative species. We show that there has been an increase in cutaneous leishmaniasis cases, both autochthonous and imported cases, over the study period. The presence of Leishmania species other than L. (L) infantum is also highlighted. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.

Author

Bosch-Nicolau, Pau, Ubals, Maria, Salvador, Fernando, Sánchez-Montalvá, Adrián, Aparicio, Gloria, Erra, Alba, Martinez de Salazar, Pablo, Sulleiro, Elena, and Molina, Israel

Subjects
*TUMOR necrosis factors, *LEISHMANIASIS, *CUTANEOUS leishmaniasis, *MONOCLONAL antibodies, *DISEASE risk factors
Abstract

Background: Tumor necrosis factor alpha (TNF-α) blockers are recognized as a risk factor for reactivation of granulomatous infections. Leishmaniasis has been associated with the use of these drugs, although few cases have been reported. Methodology: We performed a retrospective observational study including patients with confirmed leishmaniasis acquired in the Mediterranean basin that were under TNF-α blockers therapy at the moment of the diagnosis. Patients diagnosed in our hospital from 2008 to 2018 were included. Moreover, a systematic review of the literature was performed and cases fulfilling the inclusion criteria were also included. Principal findings: Forty-nine patients were analyzed including nine cases from our series. Twenty-seven (55.1%) cases were male and median age was 55 years. Twenty-five (51%) patients were under infliximab treatment, 20 (40.8%) were receiving adalimumab, 2 (4.1%) etanercept, one (2%) golimumab and one (2%) a non-specified TNF-α blocker. Regarding clinical presentation, 28 (57.1%) presented as cutaneous leishmaniasis (CL), 16 (32.6%) as visceral leishmaniasis (VL) and 5 (10.2%) as mucocutaneous leishmaniasis (MCL). All VL and MCL patients were treated with systemic therapies. Among CL patients, 13 (46.4%) were treated with a systemic drug (11 received L-AmB, one intramuscular antimonials and one miltefosine) while 14 (50%) patients were given local treatment (13 received intralesional pentavalent antimonials, and one excisional surgery). TNF-α blockers were interrupted in 32 patients (65.3%). After treatment 5 patients (10.2%) relapsed. Four patients with a CL (3 initially treated with local therapy maintaining TNF-α blockers and one treated with miltefosine) and one patient with VL treated with L-AmB maintaining TNF-α blockers. Conclusions: This data supports the assumption that the blockage of TNF-α modifies clinical expression of leishmaniasis in endemic population modulating the expression of the disease leading to atypical presentations. According to the cases reported, the best treatment strategy would be a systemic drug and the discontinuation of the TNF-α blockers therapy until clinical resolution. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

23. Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.

Author

Ubals, Maria, Bosch-Nicolau, Pau, Sánchez-Montalvá, Adrián, Salvador, Fernando, Aparicio-Español, Gloria, Sulleiro, Elena, Silgado, Aroa, Soriano-Arandes, Antoni, Espiau, Maria, Ferrer, Berta, Pou, Diana, Treviño, Begoña, Molina, Israel, and García-Patos, Vicente

Subjects
AMPHOTERICIN B, CUTANEOUS leishmaniasis, TREATMENT failure, MEDICAL personnel, LEISHMANIASIS, MEDICATION safety, DRUG utilization, MUCORMYCOSIS
Abstract

Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results